Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors

Author(s): Zhili Liu, Jing Zhang, Ao Zhang

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 6 , 2009

Become EABM
Become Reviewer


More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/ oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCRrelated very complex neurodegenerative diseases, such as Parkinsons disease (PD), Alzheimers disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.

Keywords: Multivalent ligand, G-protein-coupled receptors (GPCRs), drug design and development, heterodimerization, Parkinson's disease, Alzheimer's disease, schizophrenia, drug abuse, drug target

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [682 - 718]
Pages: 37
DOI: 10.2174/138161209787315639
Price: $65

Article Metrics

PDF: 13